Relmada Therapeutics (RLMD) announced the appointment of Raj S. Pruthi, MD as Chief Medical Officer-Urology. Dr. Pruthi’s expertise will be instrumental in the development of Relmada’s lead program, NDV-01, for non-muscle invasive bladder cancer (NMIBC). The Company presented initial Phase 2 data at the American Urology Association 2025 Annual Meeting (AUA 2025) on April 28, 2025. Raj previously served as Chief Medical Officer at enGene Holdings Inc., and as Global Medical Affairs leader at Johnson and Johnson Innovative Medicine.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLMD:
- Relmada Therapeutics Holds Annual Stockholders Meeting
- Biotech Alert: Searches spiking for these stocks today
- Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns
- VA secretary wants to find answers on psychedelics therapies, Politico says
- Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results